Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes

Heart Lung and Circulation

Volumn 20, Issue 10, 2011, Pages 647-654

  MacIsaac, Richard J ^a   Jerums, George ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cardiovascular disease; Diabetes; Glucose control; Mortality

Indexed keywords

GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; AGE; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DEATH; FOLLOW UP; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STROKE;

AGE FACTORS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; META-ANALYSIS AS TOPIC; METFORMIN; MYOCARDIAL INFARCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 80052970269     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2010.07.013     Document Type: Article

References (27)

1. Magliano D.J., Shaw J.E., Shortreed S.M., Nusselder W.J., Liew D., Barr E.L., Zimmet P.Z., Peeters A. Lifetime risk and projected population prevalence of diabetes. Diabetologia 2008, 51:2179-2186.
2. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., Williams D.E., Gregg E.W., Bainbridge K.E., Saydah S.H., Geiss L.S. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
3. Barr E.L., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., Cameron A.J., Dwyer T., Taylor H.R., Tonkin A.M., Wong T.Y., McNeil J., Shaw J.E. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116:151-157.
4. Lawes C.M., Parag V., Bennett D.A., Suh I., Lam T.H., Whitlock G., Barzi F., Woodward M. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004, 27:2836-2842.
5. Selvin E., Coresh J., Golden S.H., Brancati F.L., Folsom A.R., Steffes M.W. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005, 165:1910-1916.
6. Wei M., Gibbons L.W., Mitchell T.L., Kampert J.B., Stern M.P., Blair S.N. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 2000, 101:2047-2052.
7. Barr E.L., Boyko E.J., Zimmet P.Z., Wolfe R., Tonkin A.M., Shaw J.E. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009, 52:415-424.
8. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., Wright A.D., Turner R.C., Holman R.R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
9. Currie C.J., Peters J.R., Tynan A., Evans M., Heine R.J., Bracco O.L., Zagar T., Poole C.D. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
10. UKPDS 33 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
11. UKPDS 34 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
12. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H., Probstfield J.L., Simons-Morton D.G., Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
13. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
14. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
15. Miller M.E., Bonds D.E., Gerstein H.C., Seaquist E.R., Bergenstal R.M., Calles-Escandon J., Childress R.D., Craven T.E., Cuddihy R.M., Dailey G., Feinglos M.N., Ismail-Beigi F., Largay J.F., O'Connor P.J., Paul T., Savage P.J., Schubart U.K., Sood A., Genuth S. ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2009, 339:b5444. doi:5410.1136/bmj.b5444.
16. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
17. The Diabetes Control Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
18. The Diabetes Control Complications Trial Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
19. Brasacchio D., Okabe J., Tikellis C., Balcerczyk A., George P., Baker E.K., Calkin A.C., Brownlee M., Cooper M.E., El-Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58:1229-1236.
20. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl. 2):B21-29.
21. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
22. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., Erqou S., Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
23. Kelly T.N., Bazzano L.A., Fonseca V.A., Thethi T.K., Reynolds K., He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
24. Mannucci E., Monami M., Lamanna C., Gori F., Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009, 19:604-612.
25. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., Evans G.W., Gerstein H.C., Holman R.R., Moritz T.E., Neal B.C., Ninomiya T., Patel A.A., Paul S.K., Travert F., Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
26. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
27. Cheung N.W., Conn J.J., d'Emden M.C., Gunton J.E., Jenkins A.J., Ross G.P., Sinha A.K., Andrikopoulos S., Colagiuri S., Twigg S.M. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 2009, 191:339-344.